ABSTRACT
The 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) reported several advancements in the field of urothelial carcinoma. Multiple new treatment options for non-muscle invasive bladder cancer (NMIBC) were introduced, providing more choices for bladder preservation in BCG-resistant/failed NMIBC cases. In muscle invasive bladder cancer (MIBC) perioperative treatment, the updated 3-year follow-up data from the CheckMate 274 study demonstrated a clear advantage in disease-free survival for the nivolumab monotherapy adjuvant treatment group. For metastatic urothelial carcinoma (mUC), the final overall survival (OS) report from the IMvigor130 study was published, prompting further considerations for future first-line treatment options in mUC. Additionally, the conference highlighted research progress in upper tract urothelial carcinoma (UTUC).
ABSTRACT
The ASCO-GU 23 conference was held offline as scheduled after the pandemic. A total of 167 abstracts in the field of renal cell carcinoma has been posted during the conference, covering the first PET/CT diagnostic technology targeting tumors in renal cell carcinoma, risk stratified interpretation of the previous clinical trial results, and exploring the value of tumor and serum biomarkers for precise classification therapy, as well as providing evidence for the therapeutic scheme sequencing.
ABSTRACT
In 2022, ASCO genitourinary cancer symposium reported the latest progress in the diagnosis and treatment of urothelial carcinoma. Perioperative treatment progress include prediction of the effect of neoadjuvant chemotherapy for muscle invasive bladder cancer (MIBC) and upper urinary tract epithelial carcinoma (UTUC). The matched cohort study of bladder-sparing treatment showed that the effect of trimodality therapy (TMT) and radical cystectomy was equivalent in oncologic outcome. Immunotherapy showed promising effects in the circumstance of advanced urothelial carcinoma, neoadjuvant therapy and non muscle invasive bladder cancer (NMIBC) treatment. Poly-adenosine diphosphate ribose polymerase (PARP) inhibitors and antibody coupled drugs (ADC) show antitumor activity in the treatment of advanced urothelial carcinoma. The meeting also reported a series of progress in biomarkers related to the prediction of curative effect of urothelial carcinoma.
ABSTRACT
The 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, which took place May 31-June 4 in Chicago, drew more than 32,000 oncology specialists from around the world. The theme of 2019 ASCO conference was “Caring for Every Patient, Learning from Every Patient”. Among the topics of interest covered were new approaches to surmount limited access to cancer care and the latest advances in targeted therapies for pancreatic, prostate cancers and soft tissue sarcomas. In the field of head and neck cancer, 8 oral abstracts and 75 poster abstracts were presented at this meeting. In this review, we are going to summarize the eight studies that have been presented orally. The topics are recurrent and/or metastatic head and neck squamous cell carcinoma for two abstracts (#6000, #6002), salivary duct carcinoma for one abstract (#6001), locally advanced nasopharyngeal carcinoma for two abstracts (#6003, #6004), oropharyngeal carcinoma for two abstracts (#6006, #6008), and oral cavity cancer for one abstract (#6007).
Subject(s)
Humans , Carcinoma, Squamous Cell , Head , Head and Neck Neoplasms , Learning , Medical Oncology , Mouth , Neck , Prostatic Neoplasms , Salivary Ducts , Sarcoma , SpecializationABSTRACT
Endocrine therapy is the main treatment of hormone receptor-positive advanced breast cancer.How to reverse the endocrine resistance and the new endocrine therapy have become the focus of attention in the tumor community.The study of cyclin dependent kinase (CDKs) has developed rapidly,and the selective cdk4/6 inhibitors can significantly extend the progression-free survival of patients with endocrine resistance to breast cancer,which has been approved for standard treatment for advanced breast cancer.
ABSTRACT
It is plentiful about the 289 abstracts for the colorectal cancer (CRC) in the 2017 annual meeting of the American Society of Clinical Oncology (ASCO),which include:(1) comparison between long and short courses of postoperative adjuvant chemotherapy for stage Ⅲ CRC in the early diseases,applications of the full course of neoadjuvant therapy for locally advanced rectal cancer and laparoscopic total mesorectal excision for rectal cancer.(2) The use of Vitamin D3 and selective interstitial radiotherapy for metastatic CRC in the advanced diseases showed an encouraging efficacy.Patients with BRAF mutation and poor prognosis underwent a combination therapy of BRAF inhibitor and epidermal growth factor receptor (EGFR),which has created a new situation for precision therapy.And China's domestically designed Fruquintinib (small-molecule kinase inhibitor) and EGFR CMABO09 have showed better clinical efficacies in the second-line therapy.(3) On the precision medicine and translational researches,clinical value of consensus of molecular subtypes is being revealed and liquid biopsy is advantageous to predict postoperative tumor recurrence.These new therapies and researches would impact the clinical practices,promote clinical development and benefit the patients.
ABSTRACT
The 53rd annual meeting of the American Society of Clinical Oncology (ASCO) was held in Chicago,United States between June 2 and 6,2017.The latest advances in biliary tract cancer research from this meeting were summarized and analyzed in this paper.The adjuvant therapy in biliary tract cancer made a breakthrough in this meeting,the findings could provide the basis for a new standard of changing the current management model in the disease.The precision medicine and targeted therapy will be the development direction in the future.Doctors should attach great importance to the adjuvant and comprehensive therapy in biliary tract cancer and initiate high level multi-center clinical trials to improve the overall the diagnostic and treatment levels of biliary tract cancer.
ABSTRACT
The 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO) was held on June 2-6,2017 in Chicago,United States.And the academic event showed the frontier researches in the field of oncology.Survival prediction in patients treated by FOLFIRI regimen and bevacizumab for metastatic colorectal cancer using radiomics approach was made in Abstract 3601.Authors aim to summarize the application and development of radiomics in digestive system tumors.